Puma Biotechnology, Inc. PBYI NASDAQ

Puma Biotechnology, Inc. (PBYI) reported total assets of $216.3M and total liabilities of $85.96M for quarter ending 2025-12-31, resulting in total equity of $130.34M.

The company held $97.5M in cash and short-term investments. Total debt stood at $28.55M, with net debt of $-1.05M. The Debt-to-Equity (D/E) ratio was 0.22 (conservative).

Current ratio is 2, indicating strong short-term liquidity. Interest coverage is 15.5x (strong).

Criteria supported by this page:

• HEALTH (83/100, Pass) — Debt-to-Equity of 0.22, current ratio of 2, interest coverage 15.5x — balance sheet is strong
• MOAT (54/100) — Total assets $216.3M and equity $130.34M support the company's competitive scale
• VALUE (95/100) — Debt-to-Equity 0.22 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 69/100 with 4/7 criteria passed.